PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

Prospects, Analysis and Trends in Global Pharma 2016

The Evolution of Regulatory Operations

Steps Towards Rare Disease Success

Top Story

Europe's Cancer Dilemma

Cancer treatment is an increasing dilemma for health services in Europe as they try to balance patient care against budgetary constraints. Reflector reports
… /Read more/

Achieving Success in the Biosimilar Market
On Demand

Learn more

Deal or Delay: NICE's New Negotiating Chip

With the UK's NHS facing a financial challenge that shows no signs of abating any time soon, the National Institute for Health and Care Excellence has offered a way through the affordability challenge
… /Read more/

Supporting internal and external decision-making through effective MSL activities
On Demand

Learn more

Regulatory

FDA Tackles Cellular, Gene Therapies

FDA's new Office of Tissues and Advanced Therapies will oversee a growing range of cellular and genetic products, writes Jill Wechsler
… /Read more/

Technology can't replace people- why Patient Support Programs need a personal approach
On Demand

Learn more

Regulatory

FDA Highlights "Flexibility" in Approving Rare Disease Therapies

The FDA approved Sarepta's Exondys for Duchenne muscular dystrophy despite little evidence of efficacy, leading many to regard the decision as not being a model for future drug development
… /Read more/

Calendar

/ December 13–14: Life Sciences Trade and Channel Strategies /

Philadelphia, PA

/ February 07–08, 2017: Speaker Programs 2017 /

Philadelphia, PA

/ March 14–16, 2017: eyeforpharma Barcelona 2017 /

Barcelona, Spain

/ April 26-28, 2017: CBI's 14^th Annual Pharmaceutical Compliance Congress /

WASHINGTON, DC

/ June 6–7, 2017: Pharmaceutical Compliance Congress Canada /

Toronto, Canada

Industry update

//Henry A. McKinnell, Jr, Ph.D., retired chairman and Chief Executive Officer of Pfizer Inc., was appointed to the Board of Directors of ChemoCentryx (Mountain View, CA).//Proteon Therapeutics (Waltham, MA) appointed Paul J. Hastings as Chairman of its Board of Directors.//Recursion Pharmaceuticals (Salt Lake City, UT) named John Pereira, MBA, as Chief Operating Officer. //AltheaDx (San Diego, CA) appointed Andrew Jackson as Chief Financial Officer.//

advertise with us / print subscribe / digital subscribe / visit pharmexec.com